Biosimilars: opinion of an expert panel in the Middle East

ABSTRACT

Background: Several biotechnology-derived drugs are reaching the end of their patent lives. As a result, so-called biosimilar products are in development, and a few have already gained approval in Europe and other countries such as the USA. Biosimilars, unlike generic versions of conventional drugs, are not identical to their reference product, and their production is complex and sensitive to even slight changes in the manufacturing and storage process. Therefore, the registration of these products requires more stringent evaluation than that for conventional generics.

Methods and scope: A consensus group of experts from the Near and Middle East discussed the currently available guidelines for registration of biosimilars – including those produced by the European Medicines Agency (EMEA) – and their application in this region. To inform this report, a literature search was also conducted on PubMed in January 2008, using the search terms ‘biosimilar’ and ‘follow-on biologic’. This paper provides an overview of the issues in the development and registration of biosimilars, a description of the EMEA guidelines and the recommendations of the consensus group for the registration of biosimilars in the Middle East.

Findings: Because of the complex nature of biosimilars and their potential immunogenicity, these products cannot undergo the abbreviated approval process used for generic agents. Instead demonstration of their quality, safety and efficacy, in comparison with their reference biological product, is required.

Conclusions: The consensus group recommended the implementation of the EMEA guidelines as the basis of Regional guidelines for the registration of biosimilars in the Near and Middle East. Registration would, therefore, require demonstration of the robustness of the manufacturing process and quality-control methods, the comparability of pharmacokinetics, pharmacodynamics, efficacy and safety between the biosimilar and reference product and plans for post-marketing surveillance of the long-term risks and immunogenicity of new biosimilars.

Key words: :

• Biosimilars
• Biotechnology-derived
• Guidelines
• Immunogenicity
• Interchangeability
• Registration
• Substitution

Acknowledgements

This publication and its editorial support were supported by an unrestricted educational grant from Merck Middle East FZE. The authors have no conflicts of interest to declare for this report. The authors would like to thank Dr Briony Nicholls (freelance editorial services) for her assistance in the preparation of this manuscript.